# Luvometinib in Combination With Serplulimab for NF2-Related Tumors

> **NCT07708285** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- NF2-related Schwannomatosis
- NF2
- Neurofibromatosis Type 2
- Vestibular Schwannoma
- Meningioma

## Interventions

- **DRUG:** Luvometinib
- **DRUG:** Serplulimab

## Key facts

- **NCT ID:** NCT07708285
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708285, "Luvometinib in Combination With Serplulimab for NF2-Related Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07708285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*